BridgeMD
New treatment option for Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Official title Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT06758700
What this study is testing
What is Teniposide administration?
Teniposide administration is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for extensive-stage small cell lung cancer (es-sclc).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- extensive stage small cell lung cancer
- Progression after receiving at least one chemotherapy drug treatment in the past;
- ECOG score 0-1
- c-Myc-driven
- Expected survival period ≥3 months
You likely can't join if
- No measurable lesions
- Other severe and persistent diseases or organ system dysfunction;
- Women planning pregnancy or men planning family planning;
- Women who are pregnant or breastfeeding;
- Those who cannot follow the research protocol provided by the investigator.
See the full eligibility criteria
- extensive stage small cell lung cancer
- Progression after receiving at least one chemotherapy drug treatment in the past;
- ECOG score 0-1
- c-Myc-driven
- Expected survival period ≥3 months
- Age: 18-75 years old;
- The informed consent form complies with the ICH-GCP principles.
- No measurable lesions
- Other severe and persistent diseases or organ system dysfunction;
- Women planning pregnancy or men planning family planning;
- Women who are pregnant or breastfeeding;
- Those who cannot follow the research protocol provided by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.